Tesamorelin 5 mg is a synthetic GHRH analog (44 aa + trans-3-hexenoic acid) provided by Peptide Tech at ≥ 99% purity (HPLC & MS verified) for in-vitro, cellular, and biochemical research use only (RUO). This stabilized peptide is favored in experimental models examining GH-axis regulation, metabolic signaling, and pituitary feedback mechanisms. Supplied as a lyophilized powder with full traceability and third-party verification, Tesamorelin is optimized for reliable and reproducible laboratory research.

Specifications

Property	Details
CAS Number	218949-48-5
Chemical Name	Synthetic GHRH analog, 44 amino acids with N-terminal modification
PubChem CID	PubChem CID 16137828
Molecular Formula	C₂₂₁H₃₆₆N₇₂O₆₇S
Molecular Weight	≈ 5135.9 g/mol
Physical Appearance	White to off-white lyophilized powder
Container	3 mL glass vial (5 mg net content)
Purity	≥ 99% verified by HPLC & MS
Solubility	Soluble in sterile water or compatible buffer; gently invert until dissolved; filter-sterilize if needed

Molecular Structure

Storage & Handling

Lyophilized Storage: Store unopened vials at ≤ 6 °C (refrigerated), sealed, away from heat, light, and moisture.
For long-term storage, ≤ −20 °C is recommended.

After Reconstitution: Prepare sterile aliquots in buffer; store at ≤ −20 °C.
Avoid repeated freeze–thaw cycles to maintain peptide integrity.

Use sterile technique and aseptic conditions.
Allow vial to warm to room temperature before opening to minimize condensation.
Dissolve gently — do not vortex aggressively.
Filter-clarify if using in sterile cell culture systems.

Research Applications

(Strictly in-vitro, cellular, or biochemical contexts — no clinical or human-use claims.)

GH release modeling: Used to stimulate growth hormone secretion in pituitary culture and perfusion systems.
Endocrine regulation assays: Useful for analyzing hypothalamo-pituitary receptor pharmacology and feedback loops.
Metabolic signaling studies: Applied in models examining lipid metabolism and endocrine crosstalk.
Peptide stability comparisons: Explored in receptor-binding and degradation resistance assays.

Citations

Grunfeld, C., et al. “Effects of Tesamorelin, a Growth Hormone–Releasing Factor Analog, in HIV-Infected Patients with Abdominal Fat Accumulation.” Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 11, 2007, pp. 4265–4273. PubMed
Falutz, J., et al. “Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV.” New England Journal of Medicine, vol. 357, no. 23, 2007, pp. 2359–2370. PubMed
Allas, S., et al. “Long-Term Safety and Effects of Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Abdominal Fat Accumulation.” Journal of Acquired Immune Deficiency Syndromes, vol. 53, no. 3, 2010, pp. 311–322. PubMed
Engelson, E. S., et al. “Body Composition and Metabolic Effects of Tesamorelin in Non–HIV Adults with Abdominal Obesity.” Obesity, vol. 24, no. 6, 2016, pp. 1176–1183. PubMed
Fleseriu, M., et al. “Endocrine and Metabolic Effects of Tesamorelin, a Synthetic Growth Hormone–Releasing Factor, in Healthy Volunteers.” Journal of Clinical Pharmacology, vol. 49, no. 6, 2009, pp. 697–707. PubMed

Compliance & RUO Disclaimer

For laboratory research use only (RUO). Not for human or veterinary use, ingestion, diagnostic, or therapeutic applications.
Buyers must be qualified researchers operating under institutional guidelines.

Tesamorelin 5mg